Therapeutic Advances in Urology最新文献

{"title":"Standardized lower pole renal pelvicalyceal system measurement: a semi-autonomous approach from EAU Endourology.","authors":"Ali Talyshinskii, Andreas Skolarikos, Lazaros Tzelves, Bhaskar Kumar Somani","doi":"10.1177/17562872251396998","DOIUrl":"10.1177/17562872251396998","url":null,"abstract":"","PeriodicalId":23010,"journal":{"name":"Therapeutic Advances in Urology","volume":"17 ","pages":"17562872251396998"},"PeriodicalIF":3.5,"publicationDate":"2025-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12619894/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145542267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidental prostate cancer: is prostate-specific antigen density a valid predictor? A case-control study.","authors":"Mahmoud Farzat, Florian M Wagenlehner","doi":"10.1177/17562872251386996","DOIUrl":"10.1177/17562872251386996","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate if prostate-specific antigen density (PSAD) predicts incidental prostate cancer (iPCa) in patients undergoing robot-assisted simple prostatectomy (RASP) for benign prostatic hyperplasia (BPH).</p><p><strong>Methods: </strong>A total of 100 consecutive patients undergoing RASP for BPH were analyzed. Patients were stratified into low-risk and higher-risk groups based on their iPCa risk: 60 patients (PSAD ⩽ 0.1 ng/mL/cc) and 40 patients (PSAD > 0.1 ng/mL/cc), respectively. Outcomes included iPCa detection rates, preoperative imaging/biopsy utilization, and postoperative complications. A multivariable logistic regression and an univariate linear regression analysis were conducted to assess whether PSAD can predict the incidence of PCA.</p><p><strong>Results: </strong>iPCa was detected in 8% of cases. Five patients had <5% tumor material in their final pathology (pT1a), while three had more than 5% (pT1b). iPCa was detected in eight patients, six with International Society of Urological Pathology (ISUP) 1 and 2 with ISUP > 2. Patients with ISUP 1 were managed with active surveillance; only one chose robot-assisted radical prostatectomy, and the two with ISUP 2 and 3 opted for external radiation. Seven iPCa cases occurred in the low-PSAD group (11.7%), and one in the high-PSAD group (2.5%). In multivariate logistic regression, only a prior negative prostate biopsy was the strongest predictor of iPCa (odds ratio = 5.2, <i>p</i> = 0.01). PSAD > 0.1 ng/mL/cc was not associated (<i>p</i> = 0.09). A univariate linear regression using PSAD as a continuous variable showed no significant association (<i>p</i> = 0.27).</p><p><strong>Conclusion: </strong>PSAD, whether dichotomized (threshold of >0.1 ng/mL/cc) or continuous, didn't predict iPCa in men with large prostates. To optimize cancer detection, patients with large prostates may profit from prostate MRI before bladder outlet surgery, especially those with a history of prior prostate biopsy. Further research, including larger multicenter studies, is needed to validate our results.</p>","PeriodicalId":23010,"journal":{"name":"Therapeutic Advances in Urology","volume":"17 ","pages":"17562872251386996"},"PeriodicalIF":3.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12580511/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145446028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progression of hydronephrosis in end-stage renal disease as a potential indicator of underlying upper urinary tract tumors: a report of a rare case.","authors":"Pai-Yu Cheng, Shiu-Dong Chung, Chin-Fong Au","doi":"10.1177/17562872251393081","DOIUrl":"10.1177/17562872251393081","url":null,"abstract":"<p><p>Upper tract urothelial carcinoma (UTUC) is a rare malignancy with a higher incidence in patients with end-stage renal disease (ESRD), particularly in regions with specific environmental risk factors. The diagnosis of UTUC in patients with ESRD remains challenging because of certain limitations inherent to current urine cytology techniques and imaging quality. Herein, we report the case of a 72-year-old woman with a history of bladder urothelial carcinoma and ESRD who was receiving regular hemodialysis and was incidentally diagnosed with high-grade multifocal UTUC following a nephrectomy procedure to treat symptomatic hydronephrosis. Despite routine cystoscopic surveillance and unremarkable cytological findings, progressive hydronephrosis was noted on serial imaging. Surgical intervention was performed as the patient's symptoms worsened progressively, after which pathological examination confirmed the presence of UTUC with renal parenchymal invasion. This case highlights the notion that UTUC should be considered as a differential diagnosis in patients with ESRD exhibiting symptomatic hydronephrosis of an unexplained etiology.</p>","PeriodicalId":23010,"journal":{"name":"Therapeutic Advances in Urology","volume":"17 ","pages":"17562872251393081"},"PeriodicalIF":3.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12580510/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145446023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insights and outcomes of day-case percutaneous nephrolithotomy: results of a systematic review and single-arm meta-analysis.","authors":"Shreehari Suresh, Sylvia Ling, Dilip K Vankayalapati, Sherwin M Ganegoda, Bhaskar Somani","doi":"10.1177/17562872251389084","DOIUrl":"10.1177/17562872251389084","url":null,"abstract":"<p><strong>Background: </strong>Traditionally performed as an inpatient procedure, day-case or ambulatory percutaneous nephrolithotomy (PCNL) has emerged in recent years as a promising alternative offering the potential to reduce hospital admissions and healthcare costs, without compromising patient outcomes.</p><p><strong>Objectives: </strong>Conduct a systematic review and meta-analysis to critically evaluate the efficacy, safety and overall outcomes of day-case PCNL.</p><p><strong>Design: </strong>The systematic review was conducted in line with PRISMA guidelines (Preferred Reporting Items for Systematic reviews and Meta-Analyses).</p><p><strong>Data sources and methods: </strong>We conducted a comprehensive search of MEDLINE, Embase, Scopus, Web of Science, CENTRAL and Cochrane Databases from inception until January 2025 (CRD42024584357). The PICO statement for this systematic review is as follows: in patients with renal stones, what are the outcomes of day-case PCNL (intervention) compared with inpatient PCNL (comparator)? The authors included studies with more than 50 adult patients evaluating day-case PCNL (postoperative hospital stay ⩽ 24 h) written in the English language.</p><p><strong>Results: </strong>From an initial literature search of 2122 articles, 16 studies were identified, from which 3133 patients were included. A variety of standard, mini and ultra-mini techniques were used, with the majority opting for tubeless (61%) or totally tubeless PCNL (16%). The mean stone size was 21.5 ± 13.5 mm, with five studies including patients with renal structural abnormalities (3.6%). The pooled mean stone-free rate (SFR) was 90% (95% CI: 0.859-0.931), with a readmission rate of 3.2% (95% CI: 0.018-0.046). The overall complication rate was 10.7% (95% CI: 0.078-0.137), with most complications classified as minor with Clavien-Dindo Grade I-II (9.1%) and III-IV (1.6%). The quality assessment of the included literature revealed that all studies were of moderate to high quality.</p><p><strong>Conclusion: </strong>Day-case PCNL represents a safe and viable approach that has seen a growing adoption over recent years, driven in part by post-pandemic healthcare trends. Our review underscores its efficacy, marked by favourable outcomes and a low incidence of complications and readmissions. Moreover, detailed planning is paramount in order to establish clear criteria for potential surgical candidates and indications for inpatient admission, as well as a thorough follow-up plan.</p>","PeriodicalId":23010,"journal":{"name":"Therapeutic Advances in Urology","volume":"17 ","pages":"17562872251389084"},"PeriodicalIF":3.5,"publicationDate":"2025-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12559678/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145401674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of aggressive prostate cancer with triptorelin in real life in France: the TALISMAN study.","authors":"Thierry Lebret, Gilles Crehange, Nathalie Pello-Leprince-Ringuet, Valérie Perrot, Jérôme Rigaud","doi":"10.1177/17562872251382970","DOIUrl":"10.1177/17562872251382970","url":null,"abstract":"<p><strong>Background: </strong>Data on modalities of real-world use of androgen deprivation therapy, such as triptorelin, in men with prostate cancer (PCa) are lacking.</p><p><strong>Objectives: </strong>To describe the real-world management of triptorelin treatment over 12 months following treatment initiation in France, and to gain a better understanding of the choices being made about planned total treatment duration, formulation, and route of administration.</p><p><strong>Design: </strong>TALISMAN was a prospective, multicenter, longitudinal, non-interventional study.</p><p><strong>Methods: </strong>Patients with PCa eligible for triptorelin treatment for at least 12 months were enrolled and followed up for 12 months. The primary objective was to describe the proportion of patients treated continuously with triptorelin during the 12 months following treatment initiation. Planned total duration of treatment, formulation, administration route, and reasons for these choices were evaluated at baseline and at 6 and 12 months. Quality-of-life and safety data were collected.</p><p><strong>Results: </strong>Overall, 806 patients were enrolled, of whom 787 patients were included in the analysis. Mean (standard deviation) age was 74.0 (7.9) years, the main circumstance of prescription of triptorelin was a high-risk localized tumor (41.1%). Planned total duration of treatment at baseline was most commonly 24-36 months, and the main reasons for the choice of duration were Gleason score and guideline recommendations. Most patients (72.5%) received the 3-month subcutaneous formulation at baseline; main reasons for choice of formulation and route were physician preference and planned total duration of treatment. Overall, 85.3% (95% confidence interval (82.6, 87.7)) of patients received a continuous 12-month treatment with triptorelin, and 69.1% of patients undertook at least one supportive care pathway during the study period. Patients reported an increase in hormonal treatment-related symptoms and worsening of sexual activity and functioning. There were no new or unexpected safety findings.</p><p><strong>Conclusion: </strong>In France, compliance with continuous triptorelin treatment for 12 months is high and prescribing aligns with guideline recommendations.</p><p><strong>Trial registration: </strong>NCT04593420.</p>","PeriodicalId":23010,"journal":{"name":"Therapeutic Advances in Urology","volume":"17 ","pages":"17562872251382970"},"PeriodicalIF":3.5,"publicationDate":"2025-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12536108/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145347449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Zero residual fragment ureteroscopy: from possibility to reality - an EAU endourology perspective.","authors":"Vineet Gauhar, Daniele Castellani, Olivier Traxer, Steffi Kar Kei Yuen, Bhaskar Kumar Somani","doi":"10.1177/17562872251385044","DOIUrl":"10.1177/17562872251385044","url":null,"abstract":"","PeriodicalId":23010,"journal":{"name":"Therapeutic Advances in Urology","volume":"17 ","pages":"17562872251385044"},"PeriodicalIF":3.5,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12511685/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145281172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is there a \"Best ureteroscope\" for flexible ureteroscopy with FANS: an EAU-endourology perspective.","authors":"Vineet Gauhar, Daniele Castellani, Steffi Kar-Kei Yuen, Guohua Zeng, Thomas Herrmann, Olivier Traxer, Bhaskar K Somani","doi":"10.1177/17562872251382750","DOIUrl":"10.1177/17562872251382750","url":null,"abstract":"","PeriodicalId":23010,"journal":{"name":"Therapeutic Advances in Urology","volume":"17 ","pages":"17562872251382750"},"PeriodicalIF":3.5,"publicationDate":"2025-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12477354/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145200637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peripheral electrical stimulation for premature ejaculation: a systematic review of clinical studies.","authors":"Fateme Tahmasbi, Alireza Rahimi-Mamaghani, Farzin Soleimanzadeh, Omid Sedigh, Sarvin Sanaie, Mohsen Mohammad-Rahimi","doi":"10.1177/17562872251382317","DOIUrl":"10.1177/17562872251382317","url":null,"abstract":"<p><strong>Background: </strong>Premature ejaculation (PE) is a common sexual disorder characterized by a lack of voluntary control over ejaculation. Current treatments often fail to produce consistently satisfactory outcomes. Peripheral electrical stimulation (PES) is an emerging neuromodulation technique that applies electrical currents to targeted body areas and has shown promise across various conditions.</p><p><strong>Objectives: </strong>Although the use of PES for PE is relatively underexplored, this study aimed to synthesize existing research to better understand its potential as a treatment option.</p><p><strong>Design: </strong>Systematic review.</p><p><strong>Data sources and methods: </strong>A systematic search was conducted in PubMed, Embase, Scopus, Web of Science, and Google Scholar using relevant keywords. Studies were included if they investigated PES as a treatment for PE and reported outcomes such as intravaginal ejaculatory latency time (IELT) or other clinical measures.</p><p><strong>Results: </strong>Ten studies met the eligibility criteria. Due to the limited number and heterogeneity of studies, a meta-analysis was not feasible, and a narrative synthesis was performed. Stimulation was applied transcutaneously in various ways, including at acupuncture points, the dorsal penile nerve, and the posterior tibial nerve. Protocols varied considerably, though commonly reported parameters included a pulse frequency of 20 Hz and a pulse width of 200 µs, typically administered in 30-min sessions. Some studies lacked detailed descriptions of stimulation settings. Overall, the studies demonstrated a positive trend in favor of PES for prolonging IELT, and no consistent or significant adverse events were reported.</p><p><strong>Conclusion: </strong>The findings suggest that PES may be a promising adjunctive therapy for men with PE by prolonging IELT. Further high-quality research using validated patient-reported outcomes is needed to clarify the impact of PES on perceived ejaculatory control and sexual satisfaction.</p><p><strong>Trial registration: </strong>The study protocol was prospectively registered in PROSPERO (ID: CRD42024551360).</p>","PeriodicalId":23010,"journal":{"name":"Therapeutic Advances in Urology","volume":"17 ","pages":"17562872251382317"},"PeriodicalIF":3.5,"publicationDate":"2025-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12477390/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145200776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complications of stress urinary incontinence surgery in men: a comparative analysis of urethral sling versus artificial urinary sphincter from a large national database.","authors":"Towfik Sebai, Marwan Zein, Yara Ghandour, Baraa AlJardali, Hani Tamim, Albert El Hajj","doi":"10.1177/17562872251375528","DOIUrl":"10.1177/17562872251375528","url":null,"abstract":"<p><strong>Background: </strong>Stress urinary incontinence (SUI) in men, often due to radical prostatectomy or sphincter deficiency, impacts quality of life. Surgical options include artificial urinary sphincter (AUS) and male urethral slings, valued for lower risks and cost. Understanding their outcomes aids in patient care.</p><p><strong>Objectives: </strong>To compare 30-day postoperative outcomes in AUS versus sling implantation in males.</p><p><strong>Design: </strong>Retrospective cohort study using a multicenter database.</p><p><strong>Methods: </strong>Male patients who underwent sling or AUS implantation between 2008 and 2022 were identified in the National Surgical Quality Improvement Program (NSQIP) database using current procedural terminology (CPT) codes. Patient characteristics, intraoperative factors, and 30-day outcomes were extracted and compared. Multivariate logistic regression adjusted for age, body mass index (BMI), race, ASA classification, anesthesia technique, smoking status, history of chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF), diabetes, hypertension requiring medication, bleeding disorders, and chronic steroid use. A 1:1 propensity score-matched analysis was also conducted.</p><p><strong>Results: </strong>Among 4,498 patients, 39.6% received slings and 60.4% AUS. After adjustment, AUS was associated with higher odds of 30-day complications (OR 1.48 (1.09-2.02), <i>p</i> = 0.012), including surgical site infections (OR 2.19), overall infections (OR 1.84), implant complications (OR 4.08), genitourinary complications (OR 2.31), unplanned reoperation (OR 2.04), Clavien-Dindo Grade I-II (OR 1.58) and Grade III complications (OR 2.10), and prolonged hospital stay (OR 4.66-5.71; all <i>p</i> < 0.001). The 1:1 matched analysis largely supported these findings.</p><p><strong>Conclusion: </strong>AUS implantation is associated with higher 30-day postoperative complication rates compared to male urethral sling placement. These results may guide surgeons in their perioperative counseling regarding the short-term complication rates of both procedures, but further studies are needed to assess the long-term outcomes.</p>","PeriodicalId":23010,"journal":{"name":"Therapeutic Advances in Urology","volume":"17 ","pages":"17562872251375528"},"PeriodicalIF":3.5,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12457759/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145151009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating repeat transurethral resection after en bloc resection for non-muscle invasive bladder cancer.","authors":"Jincong Li, Yuxuan Song, Rui Chen, Hanlin Gao, Yang Liu, Yun Peng, Jilin Wu, Shicong Lai, Yiqing Du, Caipeng Qin, Tao Xu","doi":"10.1177/17562872251367555","DOIUrl":"10.1177/17562872251367555","url":null,"abstract":"<p><strong>Objective: </strong>Many studies have stressed the necessity of repeat transurethral resection (reTURB) following the initial conventional transurethral resection of the bladder for non-muscle invasive bladder cancer (NMIBC) patients. However, there have been few studies focusing on the role of reTURB after en bloc resection of bladder tumor (ERBT) for NMIBC by far. This study aimed to evaluate whether reTURB can be avoided after ERBT.</p><p><strong>Materials and methods: </strong>We conducted research in PubMed, Web of Science, EMBASE, and the Cochrane Library up to November 14, 2024, to identify studies on the reTURB after initial ERBT. For data conversion and the combined calculation of the incidence rate, we utilized R software (R Foundation for Statistical Computing, Vienna, Austria) and Cochrane Review Manager 5.4 (The Cochrane Collaboration, London, UK) along with the double arcsine method. This systematic review protocol was registered at the International Prospective Register of Systematic Reviews (PROSPERO) under number 1082989.</p><p><strong>Results: </strong>A total of 17 studies involving 1051 participants were included. The rates of residual tumor and tumor upstaging detected by reTURB or cystoscopy after ERBT were 9% (95% confidence interval (CI) = 4%-16%) and 0% (95% CI = 0%-1%). No statistically significant positive effect of reTURB after initial ERBT was exhibited in recurrence-free survival (RFS), tumor recurrence, and progression. The pooled hazard ratios of 1-year and 5-year RFS were 0.77 (95% CI = 0.41-1.44, <i>p</i> = 0.41) and 0.83 (95% CI = 0.58-1.20, <i>p</i> = 0.33). The pooled odds ratio of progression and recurrence were 1.13 (95% CI = 0.53-2.41, <i>p</i> = 0.75) and 0.78 (95% CI = 0.53-1.16, <i>p</i> = 0.23).</p><p><strong>Conclusion: </strong>ERBT can successfully regulate the rate of tumor upstaging and residual tumor to an acceptable level. For patients with NMIBC, subsequent reTURB may not be required following the initial ERBT.</p>","PeriodicalId":23010,"journal":{"name":"Therapeutic Advances in Urology","volume":"17 ","pages":"17562872251367555"},"PeriodicalIF":3.5,"publicationDate":"2025-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12415345/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145030549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}